Brian Skorney
Stock Analyst at Baird
(3.87)
# 692
Out of 5,113 analysts
121
Total ratings
49.43%
Success rate
11.15%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $80 → $88 | $100.85 | -12.74% | 6 | Dec 9, 2025 | |
| ANRO Alto Neuroscience | Maintains: Outperform | $16 → $22 | $15.33 | +43.51% | 4 | Nov 13, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $21 → $15 | $21.31 | -29.61% | 13 | Nov 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $51.32 | +20.81% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $12.18 | +326.93% | 4 | Aug 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $180 → $186 | $134.66 | +38.13% | 5 | Jul 31, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $41.60 | +190.87% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $17.70 | +80.79% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $174.83 | +45.86% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $751.13 | -21.85% | 15 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $100 | $139.72 | -28.43% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $12.08 | +148.34% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $5 | $0.09 | +5,259.06% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $12.65 | +58.10% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $27.71 | -9.78% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $342.22 | -37.17% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $7.44 | +276.34% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $11.01 | +254.22% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $41.95 | +50.18% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $477.91 | -32.00% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $26.06 | -61.63% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $0.59 | +45,998.69% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.97 | +51.13% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $0.92 | +32,651.09% | 3 | May 7, 2018 |
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $100.85
Upside: -12.74%
Alto Neuroscience
Nov 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $15.33
Upside: +43.51%
Sarepta Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $21 → $15
Current: $21.31
Upside: -29.61%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $51.32
Upside: +20.81%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $12.18
Upside: +326.93%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $180 → $186
Current: $134.66
Upside: +38.13%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $41.60
Upside: +190.87%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $17.70
Upside: +80.79%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $174.83
Upside: +45.86%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $751.13
Upside: -21.85%
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $139.72
Upside: -28.43%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $12.08
Upside: +148.34%
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.09
Upside: +5,259.06%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $12.65
Upside: +58.10%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $27.71
Upside: -9.78%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $342.22
Upside: -37.17%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $7.44
Upside: +276.34%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $11.01
Upside: +254.22%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $41.95
Upside: +50.18%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $477.91
Upside: -32.00%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $26.06
Upside: -61.63%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $0.59
Upside: +45,998.69%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.97
Upside: +51.13%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $0.92
Upside: +32,651.09%